J&J’s Third-Quarter Profit Beats Estimates on Drug Sales

Johnson & Johnson, the world’s biggest maker of health-care products, beat analysts’ earnings estimates in the third quarter on demand for new prescription medicines and medical tools acquired with the Synthes Inc. purchase. The company raised its 2012 forecast.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.